Kintara Therapeutics Q3 FY2024 net loss $2.0M ($0.05/sh), cash $6.35M; merger with TuHURA on track

TuHURA Biosciences, Inc./NV

2025-Q1 EPS reported -$0.40

Net loss of $2.0M (diluted EPS -$0.05) vs $3.3M (-$1.94) in prior-year Q3; narrower loss due to lower R&D.
Cash and equivalents $6.35M at March 31, 2024, up from $1.54M at June 30, 2023.
R&D expense fell to $0.59M from $2.01M YoY; G&A rose to $1.49M on merger-related professional fees.
Merger with TuHURA expected to close in Q3 2024; existing stockholders receive contingent value rights tied to REM-001 milestone.
REM-001 CMBC study expanded to include pembrolizumab patients; $2.0M NIH SBIR grant covers most study costs.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2024 results: net income net loss of approximately $2.0 million, EPS $0.05 per share.

Period: fiscal third quarter ended March 31, 2024
Net income: net loss of approximately $2.0 million
EPS: $0.05 per share
Result: reported results

Exact text from the filing

As of March 31, 2024, Kintara had cash and cash equivalents of approximately $6.35 million. For the three months ended March 31, 2024, Kintara reported a net loss of approximately $2.0 million, or $0.05 per share, compared to a net loss of approximately $3.3 million, or $1.94 per share, for the three months ended March 31, 2023.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-24-059716

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.